Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Satellos Bioscience Inc > they need to publish q3 financials and probably a good news
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
Comment by Steve888on Nov 22, 2017 11:36am
63 Views
Post# 27011716

RE:RE:they need to publish q3 financials and probably a good news

RE:RE:they need to publish q3 financials and probably a good news Now it is the good time to review ICO's 2017 September presentation at: https://www.icotherapeutics.com/_resources/presentations/iCo-Corporate-Presentation.pdf
75020780 wrote: My bet is either:

1. Results from Immunes testing which isn't due for a while I believe
or
2. Immune is putting in an offer to buy us out (since they will owe us a $30mil payment in first half 2018 when they begin P3 testing. And they could throw in an offer of $7-8mil right now ($0.08-$0.085 per share) and literally everyone would be on board.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities